In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
As of close of business last night, Beam Therapeutics Inc’s stock clocked out at $19.80, up 1.43% from its previous closing price of $19.52. In other words, the price has increased by $1.43 from its previous closing price. On the day, 1.27 million shares were traded. BEAM stock price reached its highest trading level at $20.1731 during the session, while it also had its lowest trading level at $19.36.
Ratios:
To gain a deeper understanding of BEAM’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.82 and its Current Ratio is at 4.82. In the meantime, Its Debt-to-Equity ratio is 0.22 whereas as Long-Term Debt/Eq ratio is at 0.20.
On March 10, 2025, Scotiabank Upgraded its rating to Sector Outperform which previously was Sector Perform but kept the price unchanged to $40.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Apr 01 ’25 when Bellon Christine sold 5,674 shares for $18.35 per share. The transaction valued at 104,122 led to the insider holds 117,294 shares of the business.
Evans John M. sold 30,663 shares of BEAM for $562,684 on Apr 01 ’25. The CEO now owns 986,249 shares after completing the transaction at $18.35 per share. On Apr 01 ’25, another insider, Ciaramella Giuseppe, who serves as the President of the company, sold 7,434 shares for $18.35 each. As a result, the insider received 136,418 and left with 190,216 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BEAM now has a Market Capitalization of 2057338752 and an Enterprise Value of 916691520. For the stock, the TTM Price-to-Sale (P/S) ratio is 31.34 while its Price-to-Book (P/B) ratio in mrq is 2.26. Its current Enterprise Value per Revenue stands at 14.432 whereas that against EBITDA is -2.329.
Stock Price History:
The Beta on a monthly basis for BEAM is 2.35, which has changed by -0.066918015 over the last 52 weeks, in comparison to a change of 0.097913146 over the same period for the S&P500. Over the past 52 weeks, BEAM has reached a high of $35.25, while it has fallen to a 52-week low of $13.52. The 50-Day Moving Average of the stock is -13.65%, while the 200-Day Moving Average is calculated to be -21.17%.
Shares Statistics:
It appears that BEAM traded 2.16M shares on average per day over the past three months and 1935580 shares per day over the past ten days. A total of 100.56M shares are outstanding, with a floating share count of 85.97M. Insiders hold about 14.51% of the company’s shares, while institutions hold 73.62% stake in the company. Shares short for BEAM as of 1744675200 were 18831497 with a Short Ratio of 8.72, compared to 1741910400 on 12163727. Therefore, it implies a Short% of Shares Outstanding of 18831497 and a Short% of Float of 21.059998999999998.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Its stock is currently analyzed by 14.0 different market analysts. The consensus estimate for the next quarter is $-1.15, with high estimates of $-0.66 and low estimates of $-1.49.
Analysts are recommending an EPS of between $-2.79 and $-5.99 for the fiscal current year, implying an average EPS of $-4.66. EPS for the following year is $-4.62, with 16.0 analysts recommending between $-2.73 and $-6.22.
Revenue Estimates
In the current quarter, 11 analysts expect revenue to total $14.68M. It ranges from a high estimate of $25M to a low estimate of $7M. As of the current estimate, Beam Therapeutics Inc’s year-ago sales were $7.41MFor the next quarter, 11 analysts are estimating revenue of $15.52M. There is a high estimate of $25M for the next quarter, whereas the lowest estimate is $10M.
A total of 15 analysts have provided revenue estimates for BEAM’s current fiscal year. The highest revenue estimate was $110M, while the lowest revenue estimate was $40M, resulting in an average revenue estimate of $63.69M. In the same quarter a year ago, actual revenue was $63.52M
